These transgenic mice have the cre recombinase gene driven by the human alpha-skeletal actin (HSA or ACTA1) promoter. When bred with mice containing a loxP-flanked sequence of interest, Cre-mediated recombination will result in striated muscle-specific deletion of the flanked genome. These mice are useful in study of spinal muscular atrophy (SMA).
IMR Colony, The Jackson Laboratory
Genetic Background | Generation |
---|---|
N11F12
|
Allele Type |
---|
Transgenic (Recombinase-expressing) |
Starting at:
$278.00 Domestic price for female 4-week |
356.51 Domestic price for breeder pair |
Mice hemizygous for this HSA-Cre79 transgene are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. These HSA-Cre79 transgenic mice have the cre recombinase gene driven by the human alpha-skeletal actin (HSA or ACTA1) promoter. Cre activity is restricted to adult striated muscle fibers and embryonic striated muscle cells of the somites and heart. When bred with mice containing a loxP-flanked sequence of interest, Cre-mediated recombination will result in striated muscle-specific deletion of the flanked genome. Specifically, these HSA-Cre79 (or ACTA1-Cre) transgenic mice were originally used to breed with mice heterozygous for a deletion of exon 7 and a loxP-flanked exon 7 mutation on homologous chromosomes of the Smn1 gene (see Stock No. 006138 or Stock No. 006146). The resulting offspring (heterozygous for the deletion in all cells and homozygous for the deletion in striated muscle cells) have extremely reduced lifespan characterized by progressive muscle necrosis and paralysis, and represent a model of spinal muscular atrophy (SMA).
Additional SMA strains expressing cre in neurons are available as well (see Stock No. 005938, Stock No. 006297, and Stock No. 006663).
HSA-Cre79 transgenic mice are also available on a different genetic background (see Stock No. 006139). In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. It should be noted that the HSA-Cre79 phenotype could vary from that originally described on a mixed genetic background. We will modify the strain description if necessary as published results become available.
Importation of this model was supported by the Spinal Muscular Atrophy Foundation. Creation and development was supported by the National Institute of Health and Medical Research of France (Inserm) and the Association Française contre les Myopathies (AFM). An additional help was provided by Families of SMA (U.S.A.) and Andrew’s Buddies (U.S.A.).
A targeting vector was designed to place a cre recombinase gene (preceded by the rabbit beta-globin intron and followed by the SV40 polyadenylation signal) under control of the human alpha-skeletal actin (HSA, ACTA1) promoter. This construct was microinjected into (C57BL6 x SJL)F1 embryos and implanted into pseudopregnant CD1 foster mothers. Founder 79 was bred to C57BL/6 to generate transgenic mice. At different points while maintaining this strain, transgenic mice were bred with C57BL/6 wild-type mice and/or mice harboring a loxP-flanked exon 7 mutation (Smn1tm1Jme or SMNF7) on a C57BL/6 and "129Sv" mixed background. Because expression of this transgene is confined to muscle tissue, Cre-mediated deletion of the floxed exon does not occur in the germline. Thus, offspring contained either the wild-type Smn1 locus or the floxed locus; never the Smn1 deletion. Transgenic offspring bearing the wild-type Smn1 locus on this mixed (but predominantly B6;129) background were sent to The Jackson Laboratory by Dr. Judith Melki in April 2006. After arriving, mutant mice were backcrossed to C57BL/6J (Stock No. 000664) for 5-10 generations.
Expressed Gene | cre, cre recombinase, bacteriophage P1 |
---|---|
Site of Expression | adult striated muscle fibers and embryonic striated muscle cells of the somites and heart |
Allele Name | transgene insertion 79, Judith Melki |
---|---|
Allele Type | Transgenic (Recombinase-expressing) |
Allele Synonym(s) | (HSA)-Cre79; HSA::cre; HSA-Cre; HSA-Cre79 |
Gene Symbol and Name | Tg(ACTA1-cre)79Jme, transgene insertion 79, Judith Melki |
Gene Synonym(s) | |
Promoter | ACTA1, actin, alpha 1, skeletal muscle, human |
Expressed Gene | cre, cre recombinase, bacteriophage P1 |
Site of Expression | adult striated muscle fibers and embryonic striated muscle cells of the somites and heart |
Strain of Origin | (C57BL/6J x SJL)F1 |
Chromosome | UN |
Molecular Note | This transgene expresses Cre recombinase under the control of a human alpha-skeletal actin promoter, active in striated muscle, heart, and skeletal muscle. |
Mutations Made By | Judith Melki, Genopole, Inserm U798 |
After arriving at The Jackson Laboratory on a mixed background, mutant mice were bred to wildtype C57BL/6J (Stock No. 000664) for 5-10 generations. The resulting backcrossed hemizygotes were maintained thereafter by breeding transgenic mice to either wildtype siblings from the colony or C57BL/6J.
When using the HSA-Cre79 mouse strain in a publication, please cite the originating article(s) and include JAX stock #006149 in your Materials and Methods section.
Service/Product | Description | Price |
---|---|---|
Hemizygous or Non carrier for Tg(ACTA1-cre)79Jme |
Frozen Mouse Embryo | B6.Cg-Tg(ACTA1-cre)79Jme/J | $2595.00 |
Frozen Mouse Embryo | B6.Cg-Tg(ACTA1-cre)79Jme/J | $2595.00 |
Frozen Mouse Embryo | B6.Cg-Tg(ACTA1-cre)79Jme/J | $3373.50 |
Frozen Mouse Embryo | B6.Cg-Tg(ACTA1-cre)79Jme/J | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.